P. André

发表

Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells

O. Lantz, R. Cohen, É. Vivier, 2018, Cell.

Analysis of the topological changes induced on cells exposed to adhesive or mechanical stimuli

P. Bongrand, A. Benoliel, C. Capo, 2008, Cell Biophysics.

A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission.

J. Bourhis, H. Dombret, D. Olive, 2012, Blood.

Comparative analysis of human NK cell activation induced by NKG2D and natural cytotoxicity receptors

M. Espéli, É. Vivier, D. Raulet, 2004, European journal of immunology.

Analysis of donor NK and T cells infused in patients undergoing MHC-matched allogeneic hematopoietic transplantation

D. Blaise, C. Chabannon, É. Vivier, 2002, Leukemia.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

Rat basophilic leukemia cells: protein kinase C and secretion.

P. Bongrand, A. Benoliel, C. Capo, 1991, Immunological investigations.

CD4+ T cell surface CCR5 density as a determining factor of virus load in persons infected with human immunodeficiency virus type 1.

M. Benkirane, J. Eliaou, J. Clot, 2000, The Journal of infectious diseases.

CD4 T cell surface CCR5 density as a host factor in HIV-1 disease progression

M. Picot, J. Eliaou, J. Clot, 2001, AIDS.

NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines

M. Welters, Pornpimol Charoentong, S. Santegoets, 2018, Cell.

A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies

G. Salles, D. Berton‐Rigaud, J. Rey, 2018, Oncotarget.

IMMUNOBIOLOGY Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD 20 antibodies

H. Kohrt, D. Czerwinski, É. Vivier, 2014 .

Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies.

H. Kohrt, D. Czerwinski, É. Vivier, 2013, Blood.

Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma.

P. Validire, C. Sautès-Fridman, W. Fridman, 2011, Cancer research.

The PEN5 epitope identifies an oligodendrocyte precursor cell population and pilocytic astrocytomas.

D. Figarella-Branger, G. Rougon, É. Vivier, 1999, The American journal of pathology.

Differential regulation of killer cell Ig‐like receptors and CD94 lectin‐like dimers on NK and T lymphocytes from HIV‐1‐infected individuals

É. Vivier, S. Guia, F. Dignat-George, 1999, European journal of immunology.

Expression of the HLA-C2-specific activating killer-cell Ig-like receptor KIR2DS1 on NK and T cells.

F. Rieux-Laucat, C. Farnarier, C. Cognet, 2010, Clinical immunology.

Association of signal-regulatory proteins beta with KARAP/DAP-12.

A. Ullrich, F. Vély, É. Vivier, 2000, European journal of immunology.

Association of signal‐regulatory proteins β with KARAP/DAP‐12

A. Ullrich, F. Vély, É. Vivier, 2000 .

Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells

A. Tosti, L. Ruggeri, A. Mancusi, 2016, Haematologica.

Flow cytometric sorting and biochemical characterization of the late endosomal rab7‐containing compartment

J. Gorvel, S. Méresse, M. Desjardins, 1997, Electrophoresis.

Effect of botulinum D toxin on human neutrophilic leukocytes and localization of its substrates.

J. Mege, P. Bongrand, C. Capo, 1990, Membrane biochemistry.

Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells.

M. Caligiuri, L. Ruggeri, A. Velardi, 2009, Blood.

Pre-clinical characterization of 1-7F9, a novel human anti-KIR therapeutic antibody that augments NK-mediated killing of tumor cells

M. Caligiuri, L. Ruggeri, A. Velardi, 2009 .

A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma.

M. Caligiuri, C. Hofmeister, S. Jagannath, 2012, Blood.

A phase 1 trial of the anti-KIR antibody IPH 2101 in patients with relapsed / refractory multiple myeloma

M. Caligiuri, C. Hofmeister, S. Jagannath, 2012 .

Evidence for Early Infection of Nonneoplastic Natural Killer Cells by Epstein-Barr Virus

R. Gascoyne, P. Trempat, P. Brousset, 2002, Journal of Virology.

Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo

É. Vivier, S. Ugolini, P. André, 2009, Proceedings of the National Academy of Sciences.

Biochemical and functional association between CD8 and H-2 at the surface of a T cell clone.

P. Bongrand, C. Boyer, A. Schmitt‐Verhulst, 1991, Molecular immunology.

Zymosan but not phorbol myristate acetate induces an oxidative burst in rat bone marrow-derived macrophages.

J. Mege, P. Bongrand, A. Benoliel, 1988, Biochemical and biophysical research communications.

Human NK cell education by inhibitory receptors for MHC class I.

D. Middleton, C. Stewart, É. Vivier, 2006, Immunity.

A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma

M. Caligiuri, C. Hofmeister, S. Jagannath, 2015, Clinical Cancer Research.

IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect.

M. Caligiuri, C. Hofmeister, D. Benson, 2011, Blood.

Differential effect of ritonavir and indinavir on immune response to hepatitis C virus in HIV-1 infected patients.

V. Lotteau, C. Michelet, C. Arvieux, 1999, AIDS.